184 publications, in the last 5 years 77 publications

 

  1. Osmani Z, Beudeker BJB, Groothuismink ZMA, de Knegt RJ, Chung RT, Aerssens J, Jacques Bollekens J, JanssenHLA, GehringAJ, Lauer GM, Alex K. Shalek AK, van de Werken HJG, Boonstra A. B cell activation gene signature in blood and liver of HBeAg+ immune active chronic hepatitis B patients. J Inf Dis. 2024 Jun 7:jiae280. 
  1. Bosch M, Kallin N, Donakonda S, Zhang JD, Wintersteller H, Hegenbarth S, Heim K, Ramirez C, Fürst A, Lattouf EI, Feuerherd M, Chattopadhyay S, Kumpesa N, Griesser V, Hoflack JC, Siebourg-Polster J, Mogler C, Swadling L, Pallett LJ, Meiser P, Manske K, de Almeida GP, Kosinska AD, Sandu I, Schneider A, Steinbacher V, Teng Y, Schnabel J, Theis F, Gehring AJ, Boonstra A, Janssen HLA, Vandenbosch M, Cuypers E, Öllinger R, Engleitner T, Rad R, Steiger K, Oxenius A, Lo WL, Klepsch V, Baier G, Holzmann B, Maini MK, Heeren R, Murray PJ, Thimme R, Herrmann C, Protzer U, Böttcher JP, Zehn D, Wohlleber D, Lauer GM, Hofmann M, Luangsay S, Knolle PA. A liver immune rheostat regulates CD8 T cell immunity in chronic HBV infection. 2024. Nature. 631(8022): 867–875.
  1. Osmani Z, Villannueva MA, Joseph-Chazan J, Beudekerr BJ, de Knegt RJ, Chung RT, Hacohen N, Aersens J, Bollekens J, Janssen HLA, Gehring AAJ, Lauer GM, Shalek AK, van de Werken HJG, Boonstra A. Intrahepatic plasma cells, but not atypical memory B cells, associate with clinical phases of chronic hepatitis B. 2024. Eur J Immunol. May 30:e2451085..
  1. Verschuren L, Linde Mak AL, Özsezen S, Difrancesco S, van Koppen A, Caspers MP, Snabel J, van der Meer D, van Dijk A-M, Badal Rashu E, Nabilou P, Parsberg Werge M, van Son K, Kleemann R, Kiliaan AJ, Hazebroek EJ, Boonstra A, Doukas M, Gupta S, Kluft C, Nieuwdorp M, Verheij J, Gluud LL, Holleboom AG, Tushuizen M, Hanemaaijer Development of a novel non-invasive biomarker panel for hepatic fibrosis in MASLD. 2024. Nature Comm. May 29;15(1):4564.
  1. Loon E, Narvaez-Barbecho C, Prieto J, Balderramo D, Carrera E, Diaz-Ferrer J, Arrese M, Mattos AZ, Boonstra A, Debes JD. Impact of Self-Reported Ancestry on the Epidemiology of Hepatocellular Carcinoma. 2024. J Gastro Hepatol. Jun;39(6):1201-1202
  1. Beudeker BJB, Guha R, Stoyanova K, IJzermans JNM, de Man RA, Sprengers D, Boonstra A. Cryptogenic non-cirrhotic HCC: Clinical, prognostic and immunological aspects of an emerging HCC etiology. 2024. Sci Rep. 14(1): 4302.
  1. Farag MS, van Campenhout MJH, Fung S, van Erpecum KJ, Wong DK, Verhey E, de Man R, Brouwer JT, Baak HC, van Nieuwkerk CM, Feld JJ, Liem KS, Boonstra A, Hansen BE, Janssen HLA. Addition of PEG-Interferon to long-term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg-negative chronic Hepatitis B. 2024. J Vir Hep. 31(4):197-207.
  1. Brakenhoff SM, Claassen M, Honkoop P, de Knegt RJ, van der Eijk AA, Boonstra A, de Man RA, Sonneveld Sustained response and HBsAg loss after nucleo(s)tide analogue discontinuation in chronic hepatitis B patients: the prospective SNAP study. 2023. Clin Res Hepatol Gastroenterol. Dec 6:102257.
  1. Beudeker BJB, Osmani Z, van Oord GW, Groothuismink ZMA, de Knegt RJ, Hoogenboezem RM, Bindels EMJ, van de Werken HJG, Boonstra A. Association of HBsAg levels with differential expression in NK, CD8 T-, and memory B cells in treated patients with chronic HBV. 2024. J Hep Rep. 6(2):100980.
  1. Devillers M, Pluimers JKF, Van Hooff MC, Doukas M, Polak W, De Man RA, Sonneveld MJ, Boonstra A, Den Hoed CM. The role of PIVKA-II as a predictor of early hepatocellular carcinoma recurrence free survival after liver transplantation in a low AFP population. Cancers. 2024. 16(1):4.
  1. Fu S, Karim D, Prieto J, Balderramo D, Diaz Ferrer J, Mattos AZ, Arrese M, Carrera E, Oliveira J, Debes JD, Boonstra A. Assessment of TLL1 variant and risk of hepatocellular carcinoma in Latin Americans and Europeans. 2023. Ann Hepatol. Nov 20;29(2):101181
  1. Fu S, Deger T, Boers RG, Boers JB, Doukas M, Gribnau J, Wilting SM, Debes JD Boonstra A. Hypermethylation of DNA methylation markers in non-cirrhotic hepatocellular carcinoma. 2023. Cancers Sep 28;15(19):4784.
  1. Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, Colombatto P, van Bömmel F, Janssen HL, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Brunetto M, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen CH, Maasoumy B; CREATE Study Group. Hepatitis B Virus DNA and Hepatitis B e Antigen Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and Hepatitis B Antigen Loss in Hepatitis B e Antigen-Negative Patients Who Discontinued Antiviral Therapy 2023. Gastroenterol. Sep 26:S0016-5085(23)05068-0. 
  1. Ayoub A, Anugwom CM, Prieto J, Balderramo D, Diaz Ferrer J, Mattos AZ, Arrese M, Carrera E, Groothuismink ZMA, Oliveira J, Boonstra A, Debes JD. Assessment of STAT4 variant and risk of Hepatocellular carcinoma in Latin Americans and Europeans. 2023. Cancers. Sep 12;15(18):4530.
  1. Goble S, Akambase J, Prieto J, Balderramo D, Ferrer JD, Mattos AZ, Arrese M, Carrera E, Groothuismink ZMA, Oliveira J, Boonstra A, Debes JD. MBOAT7 rs641738 variant is not associated with an increased risk of hepatocellular carcinoma in a Latin American cohort. 2023. Digestive Diseases and Sciences. Nov;68(11):4212-4220.
  1. Beudeker BJB, Fu S, Balderramo D, Angelo Z. Mattos AZ, Carrera E, Diaz J, Prieto J, Banales J, Vogel A, Arrese M, Oliveira J, Groothuismink ZMA, van Oord G, Hansen BE, de Man RA, Debes JD, Boonstra A. Validation and optimization of AFP-based biomarker panels for early HCC detection in Latin America and Europe. 2023. Hepatol Comm. Sep 15;7(10):e0264.
  1. Osmani Z, Boonstra A. Recent insights into the role of B cells in chronic viral hepatitis infections. 2023. 12(6): 815.
  1. Fu S, Debes JD, Boonstra A. DNA methylation Markers in the Detection of Hepatocellular Carcinoma. 2023. Eur J Cancer. Sep;191:112960.
  1. Sonneveld MJ, Chiu SM, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, Colombatto P, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Brunetto M, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen CH, Maasoumy B; CREATE study group. Lower pre-treatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg negative chronic hepatitis B patients: a multicenter cohort study. 2023. J Hep Rep. May 12;5(8):100790.
  1. Genshaft AS, Subudhi S, Keo A, Sanchez Vasquez JD, Conceição-Neto N, Mahamed D, Boeijen LL, Alatrakchi N, Oetheimer C, Vilme M, Drake R, Fleming I, Tran N, Tzouanas C, Joseph-Chazan J, Arreola Villanueva M, van de Werken HJG, van Oord GW, Groothuismink ZMA, Beudeker BJ, Osmani Z, Nkongolo S, Mehrotra A, Feld J, Chung RT, de Knegt RJ, Janssen HLA, Aerssens J, Bollekens J, Hacohen N, Lauer GM, Boonstra A, Shalek AK, Gehring A. Clinical implementation of single-cell RNA sequencing using liver fine needle aspirate tissue sampling and centralized processing captures compartment specific immuno-diversity. 2023. Hepatology Nov 1;78(5):1525-1541.
  1. LuciforaJ, Alfaiate D, Pons C, Michelet M, Ramirez R, Fusil F, AmiracheF, Rossi A, LegrandA, Charles E, VegnaS, FahratR, Rivoire M, Passot G, Godat N, Testoni B, Bach C, Baumert TF, Hyrina A, BeranRK, Zoulim F, Boonstra A, BüningH, Verrier ER, Cosset F, Fletcher SP, SalvettiA, Durantel D.Hepatitis D virus interferes with hepatitis B virus RNA production via interferon-dependent and -independent mechanisms. J Hep. 78(5): 958-970.
  1. Beudeker BJB, Groothuismink ZMA, van der Eijk AA, Debes JD, Boonstra A. Circulating cytokines reflect the etiology-specific immune environment in cirrhosis and HCC. 2022. Cancers. 14(19): 4900.
  1. Aggarwal A, Montanari NR, Ramírez R, Diehl L, Feierbach B, Boonstra A. Reply to: Hepatocyte expression of hepatitis B surface and core antigens across phases of chronic hepatitis B infection. J Hep. 2022. 77(5): 1457.
  1. Brakenhoff SM, de Knegt RJ, Oliveira J, van der Eijk AA, van Vuuren AJ, Hansen BE, Janssen HLA, de Man RA, Boonstra A, Sonneveld MJ. Anti-HBc levels are associated with liver inflammation and response to peginterferon in chronic hepatitis B patients. J Inf Dis. 2022 227(1): 113-122.
  1. Brakenhoff SM, de Knegt RJ, van Campenhout MJH, van der Eijk AA, Brouwer WP, van Bömmel F, Boonstra A, Hansen BE, Berg T, Janssen HLA, de Man RA, Sonneveld MJ. End of treatment HBsAg, HBcrAg and HBV RNA predict the risk of off-treatment ALT flares in chronic hepatitis B patients. J Microbiol Immunol and Infection. 2023. 56(1): 31-39.
  1. Hoogeveen RC, Dijkstra S, Bartsch L, Drescher H, Aneja J, Robidoux MP, Cheney JA, Fonseca de Sousa PS, Ximenez L, Baiao Peliganga L, Pitts A, Evans Blackburn F, Boonstra A, Kim AY, Lewis-Ximenez LL, Lauer GM. Hepatitis B virus-specific CD4 T cell responses differentiate functional cure from chronic surface antigen+ J Hep. 2022. 77(5): 1276-1286.
  1. Montanari NR, Ramírez R, Aggarwal A, Van Buuren N, Doukas M, Moon C, Turner S, Diehl L, Li L, Debes JD, Feierbach B, Boonstra A. Multi-parametric analysis of human livers reveals intrahepatic inflammation variation across chronic hepatitis B infection phase. J Hep. 2022. 77(2): 332-343.
  1. Gehring A, Weber J, Mendez P, Richter K, Ertl H, Donaldson E, Mishra P, Maini M, Boonstra A, Lauer G, de Creus A, Whitaker K, Ferrando-Martinez S, Miller V. Immunological Biomarker Discovery in Cure Regimens for Chronic Hepatitis B Virus Infection. J Hep. 2022. 77(2): 525-538.
  1. Sonneveld MJ, Chiu S-M, Park JY, Brakenhoff SM, Kaewdech A, Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner zu Siederdissen C, Wedemeyer H, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Chen C-H, Maasoumy B. Probability of HBsAg loss after nucleo(s)tide analogue withdrawal depends on HBV genotype and viral antigen levels. J Hep. 2022. 76(5): 1042-1050.
  1. Montanari NR, RamirezR, van BuurenN, van den BoschTPP, DoukasM, Debes JD,Feierbach B,Boonstra A. Transcriptomic analysis of livers of inactive carriers of hepatitis B virus with distinct expression of hepatitis B surface antigen. J Inf Dis. 2022. 225 (6): 1081-1090.
  1. Sonneveld MJ, Park JY,  Kaewdech A,Seto WK, Tanaka Y, Carey I, Papatheodoridi M, van Bömmel F, Berg T, Zoulim F, Ahn SH, Dalekos GN, Erler NS, Höner zu Siederdissen C, Cornberg M, Yuen MF, Agarwal K, Boonstra A, Buti M, Piratvisuth T, Papatheodoridis G, Maasoumy B. for the CREATE study group. Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels – A multicenter study (CREATE). Clin Gastro Hepatol. 2022. 20(4): e784-e793.
  1. Montanari NR; Boonstra A, Anugwom C, Debes JD. The role of cytokines in the different stages of hepatocellular carcinoma. 2021. 2021 Sep 29;13(19):4876.
  1. Sari G, Zhu J, Ambardekar C, Yin X, Boonstra A, Feng Z, Vanwolleghem T. The viral ORF3 protein is required for hepatitis E virus apical release and efficient growth in polarized hepatocytes and humanized mice. J Virol. 2021. 95(23): e0058521.
  1. Sari G, Mulders CE, Zhu J, van Oord GW, Feng Z, Kreeft-Voermans JJC, Boonstra A, Vanwolleghem T. Treatment induced clearance of HEV by IFN-lambda in liver humanized mice. Liver Intern. 2021. 41(12):2866-2873.
  1. Mattos AZ, Debes JD, Boonstra A, Vogel A, Mattos AA. Immune aspects in hepatocellular carcinoma – from immune markers for early detection to immunotherapy. World J Gastrointestinal Oncology. 2021. 13(9): 1132-1143.
  1. Beudeker BJB, Janssen HLA, Boonstra A. Letter to the Editor:  Entecavir treatment restores the anti-hepatitis B virus immune response? 2021. 71: 2325-2326.
  1. Beudeker BJB, Voermans JJC, Geurtsvankessel CH, de Knegt RJ, Kuhlemann T, Boonstra A, van der Eijk AA Prevalence of hepatitis delta virus among chronic hepatitis B carriers in a large tertiary center in the Netherlands. J Clin Virol. 2021. 141: 104870.
  1. De Mattos AZ, Debes JD Andre Boonstra A, Yang JD, Balderramo DC, Sartori GDP, Mattos AA. Current impact of viral hepatitis on liver cancer development – the challenge remains. World J Gastroenterol. 2021. 27(24): 3556-3567.
  1. Debes JD, Romagnoli P, Prieto J, Arrese M, Mattos AZ, Boonstra A. On behalf of the ESCALON Consortium. Serum biomarkers for the prediction of hepatocellular carcinoma. 2021. Apr 2;13(7):1681.
  1. Sari G, van Oord GW, van de Garde MBD, Voermans JJC, Boonstra A, Vanwolleghem T. Sexual dimorphism in hepatocyte xenograft models. Cell Transplantation. 2021. 30:9636897211006132.
  1. Kuscuoglu D, Kathrin Wenzel, Lisa Bewersdorf, Annika Gross, Gökce Kobazi Ensari, Kanishka Hittatiya, Nicole Golob-Schwarzl, Rudolf Leube, Christian Preisinger, Jacob George, Mayada Metwally, Mohammed Eslam, Pietro Lampertico, Salvatore Petta, Alessandra Mangia, Thomas Berg, Andre Boonstra, Willem P Brouwer, Maria Lorena Abate, Alessandro Loglio, Angela Sutton, Pierre Nahon, Benedikt Schäfer, Heinz Zoller, Elmar Aigner, Christian Trautwein, Johannes Haybaeck, Pavel Strnad. Dual proteotoxic stress promotes the development of liver injury via autophagy overload and activation of p62-Nrf2. J Pathology. 254: 80-91.
  1. Van Hees S, Cuypers B, Bourgeois S, Groothuismink ZMA, Meysman P, Van der Vlies P, de Knegt R, Vonghia L, Michielsen P, Francque S, Laukens K, Boonstra A, Vanwolleghem T. Sorted B cell transcriptomes point towards actively regulated B cell responses during ongoing chronic hepatitis B infections. Cell Immunol. 362: 104283.
  1. Brunetto MR, Carey I, Maasoumy B, Marcos-Fosch C, Boonstra A, Caviglia GP, Loglio A, Cavallone D, Scholtes C, Ricco G, Smedile A, Riveiro Barciela M, van Bömmel F, van der Eijk A, Zoulim F, Berg T, Cornberg M, Lampertico P, Agarwal K, Buti M. Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis. Alim Pharm Ther. 53(6): 733-744.
  1. Brakenhoff SM, de Man RA, Erler NS, Boonstra A, van Campenhout MJH, de Knegt RJ, van Bömmel F, van der Eijk AA, Berg T, Hansen BE, Janssen HLA, Sonneveld MJ. HBV RNA decline without concomitant HBsAg decrease is associated with a low probability of sustained response and HBsAg loss. Alim Pharm Ther. 53(2):314-320.
  1. Montanari NR, Conceição-Neto N, Van Den Wyngaert I, Van Oord GW, Groothuismink ZMA, Van Tilburg S, de Man RA, Aerssens J, Boonstra A. Differential gene expression in peripheral blood between low viremic inactive carrier and NUC-treated HBV patients irrespective of circulating HBsAg levels. J Inf Dis. jiaa614.
  1. Beudeker BJ, Groothuismink, ZMA, De Man RA, Witjes C, van der Eijk A, Boonstra A, Sonneveld MJ. Hepatitis B core-related antigen levels predict recurrence-free survival in patients with HBV associated early-stage hepatocellular carcinoma: Results from a Dutch long-term follow-up study. J Vir Hep. 28(1): 205-208.
  1. Debes JD, Groothuismink ZMA, de Man RA, Boonstra A. Association between a progesterone receptor mutation and hepatitis E sero-positivity in liver transplant recipients. J Med Virol.10.1002/jmv.26236.
  1. Beudeker BJ, Groothuismink ZM, de Man RA, Janssen H, van der Eijk AA, Boonstra A, Sonneveld MJ. Hepatitis B core-related antigen levels predict pegylated interferon-α therapy response in HBeAg-positive chronic hepatitis B.

Antivir Ther. 2021. 28(1): 205-208.

  1. Shen S, Wong GL-H, Kuang Z, van Campenhout MJH, Fan R, Wong VW-S, Yip TC-F, Chi H, Liang X, Hu X, Lin W, Wu Y, Liu X, Boonstra A, Hou J, Sun J, Chan HL-Y. Development and validation of a model for hepatitis B e antigen seroconversion in entecavir‐treated patients with chronic hepatitis B. J Med Virol. 92(8): 1206-1213.
  1. Beudeker BJB, Boonstra A. Circulating biomarkers for early detection of hepatocellular carcinoma. Therapeutic Advances in Gastroenterology. 2020. 3:1756284820931734
  1. Hakim MS. Jariah ROA, Spaan M, Boonstra A. Interleukin 15 upregulates the expression of PD-1 and TIM-3 on CD4+ and CD8+ T cells. Amer J Clin Exp Immunol. 9(3):10-21.
  1. Boeijen LL, Spaan M, Boonstra A. The effect of nucleo(s)tide analogs on host immune cells: the baseline for future immune therapy for HBV? Antiviral Therapy. 2020. 25(4): 181-191.
  1. Debes JD, van Oord GW, Boonstra A. Validation of whole blood rapid diagnosis test for hepatitis B. Annals of Global Health. 86(1): 53, 1–2.
  1. Van Campenhout MJH, van Bömmel F, Pfefferkorn M, Fischer J, Deichsel D, Boonstra A, van Vuuren AJ, Berg T, Hansen BE, Janssen HLA. Serum hepatitis B virus RNA predicts response to peginterferon treatment in HBeAg positive chronic hepatitis B. J Vir Hep. 27(6): 610-619.
  1. Vanwolleghem T, Groothuismink ZMA, Kreefft K, Hung M, Novikov N, Boonstra A. Potent Hepatitis B core-specific memory B cell responses associate with clinical parameters in chronic HBV patients. J Hepatol. 2020 Jul;73(1):52-61.
  1. Debes JD, Boonstra A, de Knegt RJ. NAFLD-related HCC and the four horsemen of the Apocalypse. 2020. 71(3): 774-776.
  1. Hoogeveen RC, Boonstra A. Checkpoint inhibitors and therapeutic vaccines for the treatment of chronic hepatitis B virus infection. Frontiers in Immunol. 11; 401.
  1. Sari G, Meester EJ, van der Zee LC, Wouters K, van Lennep JR, Peppelenbosch M, Boonstra A, Van der Heiden K, Mulder MMT, Vanwolleghem T. A mouse model of humanized liver shows a human-like lipid profile, but does not form atherosclerotic plaque after western type diet. Biochem Biophys Res Commun. 524(2):510-515.
  1. Farag MS, van Campenhout MJH, Pfefferkorn M, Fischer J, Deichsel D, Boonstra A, van Vuuren AJ, Ferenci P, Feld JJ, Berg T, Hansen BE, van Bömmel F, Janssen HLA. HBV-RNA in serum as early predictor for response to PEGylated interferon alfa treatment in HBeAg negative chronic hepatitis B. Clin Infec Dis. 72(2):202-211..
  1. Sari G, van de Garde MDB, van Schoonhoven A, Voermans JC, van der Eijk AA, de Man RA, Boonstra A, Vanwolleghem T, Pas SD. HEV shows more genomic alterations in vitro than in vivo. 2019. 8(4):255.
  1. Debes JD, Groothuismink ZMA, Doukas M, de Man RA, Boonstra A. Immune dissociation during acute hepatitis E infection. Int J Inf Dis. 87:39-42.
  1. Debes JD, Carrera E, Mattos AZ, Prieto JE, Boonstra A. ESCALON investigators. Hepatocellular carcinoma, a unique tumor with a lack of biomarkers. Ann Hepatol. 2019. 18(6):786-787.
  1. Leathers J, Pisano MB, Re V, van Oord G, Sultan A, Boonstra A, Debes JD. Evaluation of rapid diagnostic tests for assessment of hepatitis B in resource limited settings. Ann Global Health. 11(4):314-315.
  1. Debes JD, Boonstra A, Balderramo D, Mattos AZ, Arrese M. Hepatobiliary cancers in South America, where disparity strikes. Lancet Gastro Hepatol. 4(8): 581.
  1. Das T, Bergen IM, Koudstaal T, van Hulst JAC, van Loo G, Boonstra A, Vanwolleghem T, Leung PSC, Reis e Sousa C, Hendriks RW, Kool M. T cell and B cell homeostasis is controlled by A20/Tnfaip3 levels in DNGR1+ DCs inducing autoimmune liver pathology. J Autoimmun. 2019. 102: 167-178.
  1. Revill PA, Block J, Chisari F, Dandri M, Gehring, A, Guo H, Hu J, Kramvis A, Lampertico P, Janssen HLA, Levrero M, Li W, Liang J, Lim SG, Lu F, Penicaud C, Tavis J, Thimme R, Members of the ICE-HBV Working Groups, ICE-HBV Stakeholders Group Chairs, ICE-HBV Senior Advisors, and Zoulim F. The International Coalition to Eliminate Hepatitis B (ICE-HBV) – A Global Scientific Strategy towards Cure of Chronic Hepatitis B Virus Infection. Lancet Gastro Hepatol. 4(7): 545-558.
  1. Soares E, Groothuismink ZMA, Boonstra A, Bolges O. Glucan particles are a powerful adjuvant for the HBsAg, favoring antiviral immunity. Mol Pharmaceutics. 16(5): 1971-1981.
  1. Newsum AM, Kooij KW, Boyd A, Smit C, Boonstra A, Rijnders B, Wit FWNM, van der Meer JTM, Prins M, Reiss P, van der Valk M; MOSAIC study group, ATHENA observational HIV cohort and NVHB-SHM hepatitis working group. Progression of liver fibrosis following acute hepatitis C virus infection in HIV-positive MSM. 2019 Apr 1;33(5):833-844.
  1. Van Halewijn GJ, Geurtsvankessel CH, Klaasse J, van Oord GW, de Knegt RJ, van Campenhout MJ, Boonstra A, van der Eijk AA. Diagnostic and analytical performance of the hepatitis B core related antigen immunoassay in hepatitis B patients. J Clin Virol. 114: 1-5.
  1. Sonneveld MJ, van Oord GW, van Campenhout MJ, de Man RA, Janssen HLA, de Knegt RJ, Boonstra A, van der Eijk AA. Relationship between hepatitis B core related antigen levels and sustained HBeAg seroconversion in patients treated with nucleo(s)tide analogues. J Vir Hep. 26(7): 828-834.
  1. Brouwer WP, Chan HLY, Lampertico P, Hou J, Tangkijvanich P, W Reesink HW, Zhang W, Mangia A, Tanwandee T, Montalto G, Simon K, Ormeci N, Chen L, Tabak F, Gunsar F, Flisiak R, Ferenci P, Akdogan M, Akyuz F, Hirankarn N, Jansen L, Wong V, Liang X, Shalom Chen S, Groothuismink ZMA, Jaroszewicz J, Ozaras R, Kozbial K, Brahmania M, Xie Q, Chotiyaputta W, Xun Q, Pazgan-Simon M, Oztas E, Verhey E, Montanari NR, Sun J, Hansen BE, Boonstra A, Janssen For the GIANT-B Global Consortium. Genome wide association study identifies variants associated with early and sustained response to interferon in chronic hepatitis B patients: the GIANT-B study. Clin Inf Dis. 2019. 69(11): 1969-1979.
  1. Leathers J, Pisano MB, Re V, van Oord G, Sultan A, Boonstra A, Debes JD. Validation of a point-of-care rapid diagnostic test for hepatitis C for use in resource-limited settings. International Health. 11(4): 314-315.
  1. Boeijen LL, van Oord GW, Hou J, van der Heide-Mulder M, Gaggar A, Li L, Fletcher SP, de Knegt RJ, Boonstra A. Gene expression profiling of human tissue resident immune cells: comparing blood and liver. J Leukoc Biol. 105(3): 603-608.
  1. Hoogeveen RC, Robidoux MP, Schwarz T, Cheney JA, Kvistad D, Aneja J, Chung RT, Boonstra A, Kim AY, Timm J, Lewis-Ximenez LL, Tonnerre P, and Lauer GM. Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection. 2019. 68(5):893-904.
  1. Shah SM, Baniya JB, Gupta B, Shrestha A, Rodin H, Boonstra A, Debes JD. Association between liver fibrosis and Hepatitis E seroprevalence among HIV-positive individuals in Nepal. Eur J Gastroenterol Hepatol. 31(4): 503-505.
  1. Van Campenhout MJH, Rijckhorst V, Brouwer WP, Ferenci P, Tabak F, Akdogan M, Pinarbasi B, Simon K, Raptopoulou-Gigi, van Oord G, de Knegt RJ, Boonstra A, Janssen HLA, Hansen BE. Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B. J Vir Hep. 2019. 26(10): 1156-1163.
  1. Boeijen LL, Hou J, de Groen RA, Verbon A, Boonstra A. Persistent replication of HIV, HCV and HBV results in distinct gene expression profiles by human NK cells. J Virol 93(9): e00575-18.
  1. El Sharkawy R, Thabet K, Lampertico P, Petta S, Mangia A, Berg T, Metwally M, Boonstra A, Brouwer WP, Lorena Abate M, D’Ambrosio R, Douglas MW, Khan A, Fischer J, Liddle C, George J, Eslam M. STAT4 variants increase liver fibrosis risk in chronic hepatitis B through impaired STAT4-dependent NK cell IFN-γ production. Alim Pharm Ther. 48(5):564-573.
  1. RomaniS, Hosseini SM, Mohebbi SR, Boonstra A, Hosseini Razavi A, Sharifian A. Characterization of the “a” determinant region of the hepatitis B virus genome in Iranian patients at different clinical phases of chronic infection. Gastroenterol Hepatol Bed Bench. 11(2):131-137.
  1. Peltenburg NC, Schoeman JC, Hou J, Mora F, Harms AC, Lowe SH, Bierau J, Bakker JA, Verbon A, Hankemeier T, Boonstra A. Persistent metabolic changes in HIV infected patients during the first year of combination antiretroviral therapy. Scientific Reports. 2018 Nov 16;8(1):16947.
  1. Buschow SI, P Biesta, NS Erler, ZMA Groothuismink, T Vanwolleghem, I Najera, M Ait-Goughoulte, A Boonstra, AM Woltman. TLR7 polymorphism, HBV infection and sex affect plasmacytoid DC phenotypic maturation by TLR7 (but not TLR9) ligands. Antivir Res. 2018 Sep;157:27-37.
  1. Debes JD, Pas SD, Groothuismink ZMA, van der Ende ME, de Man RA, Boonstra A. A mutation in the progesterone predisposes to HEV infection in HIV-positive patients. Liver Int. 2018. 38(5):792-796.
  1. Van Campenhout MJH, van Bommel F, Grossmann M, Fischer J, Deichsel D, Boonstra A, van Vuuren A, Berg T, Hansen BE, Janssen HLA. Host and viral factors associated with serum hepatitis B virus RNA levels among patients in need for treatment. Hepatology. 2018 Sep;68(3):839-847.
  1. Debes JD, van Tilborg M, Groothuismink ZMA, Hansen BE, Schulze zur Wiesch J, von Felden J, de KnegtRJ, Boonstra A. Levels of cytokines in serum associate with development of hepatocellular carcinoma in patients with HCV infection treated with direct-acting antivirals. 2018. Feb; 154(3):515-517.
  1. Beudeker BJ, van Oord GW, Arends JA, Schulze zur Wiesch, van der Heide M, de Knegt RJ, Verbon A, Boonstra A, Claassen MAA. MAIT cell frequency and function in blood and liver of HCV mono- and HCV/HIV co-infected patients with mild versus advanced fibrosis. Liver Int. Mar;38(3):458-468.
  1. Boeijen LL, Montanari NR, de Groen RA, van Oord GW, van der Heide M, de Knegt RJ, Boonstra A. Mucosal-associated invariant T (MAIT) cells are more activated in chronic hepatitis B, but not depleted in blood: reversal by antiviral therapy. J Inf Dis. 216(8):969-976
  1. Shrestha A, Adhikari A, Bhattarai M, Rauniyar R, Debes JD, Boonstra A, Lama TK, Al Mahtab M, Butt A, Fazle Akbar SM, Aryal N, Karn S, Das Manandhar K, Gupta BP. Prevalence and risk of hepatitis E virus infection in the HIV population of Nepal. Virology J. Nov 21;14(1):228.
  1. Van de Garde M, Pas SD, van Oord GW, Gama L, Choi Y, de Man RA, Boonstra A, Vanwolleghem T. Interferon-alpha treatment rapidly clears Hepatitis E virus infection in humanized mice. Scientific Reports. 7(1):8267.
  1. Hou J, Brouwer WP, Kreefft K, Janssen HLA, French PJ, Vanwolleghem T, Boonstra. Unique liver transcriptomics profiles in chronic hepatitis B: intrinsic intrahepatic functional clusters discriminate distinct clinical phases. PlosOne. 2017. 12(6):e0179920.
  1. Van den Dries L, Claassen MAA, Groothuismink ZMA, van Gorp E, Boonstra A. Immune activation in prolonged cART-suppressed HIV patients is comparable to that of healthy controls. Virology. 2017. 509:133-139.
  1. Boeijen LL, Hoogeveen RC, Boonstra A, Lauer GM. Hepatitis B virus infection and the immune response: the big questions. Best Pract Res Clin Gastroenterol. 31(3):265-272.
  1. De Groen RA, Groothuismink ZMA, van Oord GW, Kootstra NA, Janssen HLA, Prins M, Schinkel J, Boonstra A. NK cells in self-limited HCV infection exhibit a more extensively differentiated CD57+/KIR+ and NKG2A–, but not memory-like, repertoire. J Vir Hep. 2017. 24: 917-926.
  1. Brouwer WP, van der Meer AJ, Boonstra A, Plompen EPC, Pas SD, de Knegt RJ, de Man RA, ten Kate FJW, Janssen HLA, Hansen BE. Prediction of long-term clinical outcome in a diverse chronic hepatitis B population: Role of the PAGE-B score. J Vir Hep. 2017. 24: 1023-1031.
  1. Hullegie SJ, Arends JEA, Groothuismink ZMA, Pas SD, Rijnders BJA, Boonstra A, Claassen MAA. Decreased pro-inflammatory immune responses during recurrent acute HCV re-infections in HIV co-infected patients. J Gen Virol 98(6): 1294-1298.
  1. Vanwolleghem T, Boonstra A. Focus on the liver: host–virus interactions in HBV. J Hepatol. 66(5): 884-885.
  1. Romani S, Hosseini SM, Mohebbi SR, Boonstra A, Sharifian A. Differential expression of innate immune response genes in clinical phases of chronic hepatitis B infection. J Vir Hep. 24(9): 776-788.
  1. De Groen RA, Hou J, van Oord GW, Groothuismink ZMA, van der Heide M, de Knegt RJ, Boonstra A. NK cell phenotypic and functional shifts coincide with specific clinical phases in the natural history of chronic HBV infection. Antivir Res. 140:18-24.
  1. Thabet K, Chan HL, Petta S, Mangia A, Berg T, Boonstra A, Brouwer WP, Abate ML,  Wong V, White R,  Fischer J, Liddle C, George J, Eslam M. The MBOAT7 variant rs641738 increases inflammation and fibrosis in chronic hepatitis B. 2017. 65(6): 1840-1850.
  1. Debes JD, de Knegt RJ, Boonstra A. The path to cancer, and back: Immune modulation during hepatitis C virus infection, progression to fibrosis and cancer, and unexpected roles of new antivirals. 2017. 101(5):910-915.
  1. Debes JD, Janssen HLA, Boonstra A. Hepatitis C treatment and liver cancer recurrence: cause for concern? Lancet Gastroenterology and Hepatology. 2(2): 78-80.
  1. Van de Garde MDB, Movita D, van der Heide M, Herschke F, de Jonghe S, Gama L, Boonstra A, Vanwolleghem T. Liver monocytes and Kupffer cells remain transcriptionally distinct during chronic viral infection. 2016. 11(11):e0166094.

 

  1. Debes JD, Bohjanen PR, Boonstra A. Mechanisms of accelerated liver fibrosis progression during HIV infection. J Clin Transl Hepatol. 4(4): 328-335.
  1. Verstrepen BE, Nieuwenhuis IG, Mooij, Verschoor EJ, Fagrouch ZC, Kondova I, Boonstra A, Koopman G. Role for microbial translocation in soluble CD14 up-regulation in HIV, but not in HCV, infected chimpanzees. J Gen Virol. 97(10): 2599-2607.
  1. Spaan M, Hullegie SJ, Beudeker BJB, Kreefft K, van Oord GW, Groothuismink ZMA, van Tilborg M, Rijnders B, de Knegt RJ, Claassen MAA, Boonstra A. Frequencies of circulating MAIT cells are diminished in chronic HCV, HIV and HCV/ HIV co-infection and do not recover during therapy. 2016.11(7): e0159243.
  1. Schoeman JC, Hou J, Harms AC, Vreeken RJ, Berger R, Hankemeier T, Boonstra A. Integrating metabolomics and transcriptomics to characterise the natural progression of chronic hepatitis B. Genome Medicine. 8(1): 64.
  1. Tjwa ETTL, Zoutendijk R, van Oord GW, Boeijen LL, Reijnders JGP, van Campenhout MJH, de Knegt RJ, Janssen HLA, Woltman AM, Boonstra A. Similar frequencies, phenotype and activation status of intrahepatic NK cells in chronic HBV patients after long-term treatment with tenofovir disoproxil fumarate (TDF). Antivir Res. 132: 396-404.
  1. Van Campenhout MJH, Brouwer WP, van Oord GW, Xie Q, Zhang Q, Zhang N, Guo S, Tabak F, Streinu-Cercel A, Wang J.-Y, Pas SD, Sonneveld MJ, de Knegt RJ, Boonstra A, Hansen BE, Janssen HLA. Hepatitis B core-related antigen levels are associated with response to entecavir and peginterferon add-on therapy in HBeAg-positive chronic hepatitis B patients. Clin Microbiol Infection. 22(6): 571.e5-9.
  1. Van de Garde MDB, Pas SD, van der Net G, Osterhaus ADME, Haagmans BL, Boonstra A, Vanwolleghem T. Hepatitis E virus genotype three infection of human liver chimeric mice as a model for chronic HEV infection. J Virol. 90: 4394-4401.
  1. Verstrepen B, Nieuwenhuis I, Mooij P, Bogers W, Boonstra A, Koopman G. Spontaneous and NCR mediated cytotoxicity are effector functions of distinct NK subsets in HCV infected chimpanzees. Clin Exp Immunol. 2016. 185: 42-49.
  1. Schoufour JD, Echteld MA, Boonstra A, Groothuismink ZMA, Evenhuis HM. Biochemical measures and frailty in people with intellectual disabilities. Age and Aging. 2016 Jan;45(1):142-148.
  1. Spaan M, van Oord G, Kreefft K, Hou J, Hansen BE, Janssen HLA, de Knegt RJ, Boonstra A. Immunological analysis during interferon-free therapy for chronic hepatitis C virus infection reveals modulation of the natural killer cell compartment. J Inf Dis. 213(2): 216-23.
  1. Vanhommerig JW, Lambers FA, Schinkel J, Geskus RB, Arends JE, van de Laar TJ, Lauw FN, Brinkman K, Gras L, Rijnders BJ, van der Meer JT, Prins M; MOSAIC (MSM Observational Study of Acute Infection With Hepatitis C) Study Group, van der Meer JT, Molenkamp R, Mutschelknauss M, Nobel HE, Reesink HW, Schinkel J, van der Valk M, van den Berk GE, Brinkman K, Kwa D, van der Meche N, Toonen A, Vos D, van Broekhuizen M, Lauw FN, Mulder JW, Arends JE, van Kessel A, de Kroon I, Boonstra A, van der Ende ME, Hullegie S, Rijnders BJ, van de Laar TJ, Gras L, Smit C, Lambers FA, Prins M, Vanhommerig JW, van der Veldt W. Risk factors for sexual transmission of hepatitis C virus among human immunodeficiency virus-infected men who have sex with men: a case-control study. Open Forum Infect Dis. 2015 Aug 6;2(3):ofv115.
  1. Maan R, van der Meer AJ, Brouwer WP, Plompen EPC, Sonneveld MJ, Roomer R, van der Eijk AA, Groothuismink ZMA, Hansen BE, Veldt BJ, Janssen HLA, Boonstra A, de Knegt RJ. ITPA polymorphisms are associated with hematological side effects during antiviral therapy for chronic HCV infection. PLoS ONE. 10(10): e0139317.
  1. Spaan M, van Oord GW, Janssen HLA, de Knegt RJ, Boonstra A. Longitudinal analysis of peripheral and intrahepatic NK cells in chronic HCV patients during triple therapy. Antivir Res. 123:86-92.
  1. Debes JD, Bohjanen PR, Boonstra A. Liver fibrosis in HIV and HCV co-infection: independent mechanisms versus collective efforts. Int J Virol AIDS. 2: 008.
  1. de Groen RA, Groothuismink ZMA, Liu BS, Boonstra A. IFN-λ is able to augment TLR-mediated activation and subsequent function of primary human B cells. J Leukoc Biol. 2015. 98: 623-630.
  1. Vanwolleghem T, Hou J, van Oord G, Andeweg AC, Osterhaus ADME, Pas SD, Janssen HLA, Boonstra A. Re-evaluation of HBV clinical phases by system biology identifies unappreciated roles for the innate immune response and B cells. 2015. 62(1): 87-100.
  1. Spaan M, Claassen MA, Hou J, Janssen HLA, de Knegt RJ, Boonstra A. The intrahepatic T-cell compartment does not normalize years after therapy-induced hepatitis C virus eradication. J Inf Dis. 2015. 212(3): 386-390.
  1. Movita D, van de Garde M, Biesta P, Kreefft K, Haagmans B, Zuniga E, Herschke F, De Jonghe S, Janssen HLA, Boonstra A, Vanwolleghem T. Inflammatory monocytes are the central instigators of early virus-induced liver inflammation. J Virol. 89(9): 4809-4817.
  1. Verstrepen BE, Boonstra A, Koopman G. Immune mechanisms of vaccine induced protection against chronic HCV infection in chimpanzees. World J Hepatol. 7(1): 53-69.
  1. Hou J, Boonstra A. Modulation of Toll-like receptor 9 expression by monocytes of viral hepatitis patients. Antivir Ther. 2015. 20(6): 667-668.
  1. De Graav GN, Dieterich M, Hesselink DA, Boer K, Clahsen-van Groningen MC, Kraaijeveld R, Litjens NHR, Bouamar R, Vanderlocht J, Tilanus M, Houba I, Boonstra A, Roelen DL, Claas FHJ, Betjes MGH, Weimar W, Baan CC. Follicular T-helper cells and humoral reactivity in kidney-transplant patients. Clin Exp Immunol. 180(2): 329-340.
  1. De Groen RA, Boltjes A, Hou J, Liu B-S, Mcphee F, Friborg J, Janssen HLA, Boonstra A. IFNλ-mediated IL-12 production in macrophages induces IFNγ production in human NK cells. Eur J Immunol. 45(1): 250-259.
  1. Boltjes A, van Montfoort N, Biesta PJ, Op den Brouw ML, Kwekkeboom J, van der Laan LJW, Janssen HLA, Boonstra A, Woltman AM. Kupffer cells interact with HBsAg in vivo and in vitro leading to pro-inflammatory cytokine production and NK cell function. J Inf Dis. 211(8):1268-1278.
  1. Spaan M, Kreefft K, Brouwer WP, de Knegt RJ, Ten Kate FJW, Vanwolleghem T, Janssen HLA, Boonstra A. CD4+CXCR5+ T cells in HCV infection are less capable of producing IL-21 but have a good ability to perform B cell help. J Hepatol. 62(2): 303-310.
  1. Brouwer WP, van der Meer AJ, Boonstra A, Pas S, de Knegt RJ, Hansen BE, ten Kate FJW, Janssen HLA. The impact of PNPLA3 (rs738409c>g) on liver histologic changes is modified by gender and overweight in chronic hepatitis B patients. Liver Int. 2015. 35(2): 438-447.
  1. Hou J, van Oord G, Groothuismink ZMA, Claassen MAA, Kreefft K, Zaaraoui-Boutahar F, van IJcken WFJ, Osterhaus ADME, Janssen HLA, Andeweg AC, de Knegt RJ, Boonstra A. Gene expression profiling to predict and assess the consequences of therapy-induced virus eradication in chronic HCV. J Virol. 88(21): 12254-12264.
  1. Hou J, Groothuismink ZMA, Koning L, Roomer R, van IJcken WFJ, Kreefft K, Liu BS, Jansen HLA, de Knegt RJ, Boonstra A. Analysis of the transcriptome and immune function of monocytes during IFNα-based therapy in chronic HCV revealed induction of TLR7 responsiveness. Antivir Res. 109: 116-124.
  1. Brouwer WP, Sonneveld MJ, Tabak F, Simon K, Cakaloglu Y, Akarca US, Zeuzem S, Ferenci P, Heathcote JE, de Knegt RJ, Boonstra A, Hansen BE, Janssen HLA. Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B. Alim Pharm Ther. 40: 811-818.
  1. Boltjes A, Movita D, Woltman AM, Boonstra A. The role of Kupffer cells in viral hepatitis. J Hepatol. 61: 660-671.
  1. Boltjes A, Groothuismink ZMA, Janssen HLA, Woltman AM, Boonstra A. Monocytes from chronic HBV patients react in vitro to HBsAg and TLR by producing cytokines irrespective of stage of disease. PLoS ONE. 2014 May 13;9(5):e97006.
  1. Hakim MS, Spaan M, Janssen HLA, Boonstra A. Inhibitory receptor molecules in chronic hepatitis B and C Infections: novel targets for immunotherapy? Med Rev Virol. 2014 24(2): 125-138.
  1. De Groen RA, Liu BS, Boonstra A. Understanding IFN-lambda in rheumatoid arthritis. Arthritis Res Ther. 16(1): 102.
  1. De Groen RA, Mcphee F, Friborg J, Janssen HLA, Boonstra A. Endogenous IFNλ in viral hepatitis patients. J Interferon & Cytokine Res. 34: 552-556.
  1. Claassen MAA, Janssen HLA, de Knegt RJ, Boonstra A. Controversy on the role of FoxP3+ regulatory T cells in fibrogenesis in chronic hepatitis C virus infections. J Hepatol. 60: 231-232.
  1. Nikolic T, Movita D, Lambers M, Ribeiro de Almeida C, Biesta P, Kreefft K, de Bruijn JW, Bergen I, Galjart N, Hendriks R, Boonstra A. The DNA-binding factor CTCF critically controls gene expression in macrophages. Cell Mol Immunol. 11: 58-70.
  1. Claassen MAA, Janssen HLA, Boonstra A. Role of T cell immunity in hepatitis C virus infections. Curr Opin Virol. 3: 461-467.
  1. Tjwa ETTL, Zoutendijk R, van Oord GW, Verhey J, Janssen HLA, Woltman AM, Boonstra A. Intrahepatic NK cell activation, but not function, is associated with HBV-DNA and HBsAg in patients with chronic hepatitis B. Liver Int. 34(3): 396-404.
  1. Spaan M, Groothuismink ZMA, Koning L, Robert R, Janssen HLA, de Knegt RJ, Boonstra A. Erythropoietin administration suppresses human monocyte function in vitro and during therapy-induced anemia in HCV patients. Antiviral Res. 98: 469-475.
  1. Hotho DM, de Bruijne J, Spaan M, Treitel MA, Boonstra A, de Knegt RJ, Janssen HLA, Reesink HW. Sustained virologic response after therapy with the protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable during long-term follow-up. J Vir Hep. 20 (4): e78-81.
  1. Hotho DM, Kreefft K, Groothuismink ZMA, Janssen HLA, de Knegt RJ, Boonstra A. Natural killer cell activity and function in chronic HCV-infected patients during peginterferon and ribavirin: early effects of active substance use. Antiviral Res. 97 (3): 347-355.
  1. Sonneveld MJ, Arends P, Boonstra A, Hansen BE, Janssen HL. Serum levels of interferon gamma-inducible protein-10 and response to peginterferon therapy in HBeAg-positive Chronic Hepatitis B. J Hepatol. 58 (5): 898-903.
  1. van der Meer AJP, Farid WRR, Sonneveld MJ, de Ruiter PE, Boonstra A, van Vuuren AJ, Verheij J, Hansen BE, de Knegt RJ, van der Laan LJ, Janssen HLA. Sensitive detection of hepatocellular injury in chronic hepatitis C patients with circulating hepatocyte-derived microRNA-122. J Vir Hep. 20 (3): 158-166.
  1. Boltjes A, Op den Brouw ML, Biesta PJ, Binda RS, van der Molen RG, Boonstra A, Janssen HLA, Woltman AM. Assessment of the effect of ribavirin on myeloid and plasmacytoid dendritic cells during interferon-based therapy of chronic HBV patients. Mol Immunol. 53 (1-2): 72-78.
  1. Zoutendijk R, Sonneveld MJ, Reijnders J, van Vuuren AJ, Biesta P, Hansen BE, Boonstra A, Janssen Precore and core promoter mutants are associated with higher HBeAg seroconversion but lower disease remission rates in HBV patients treated with nucleos(t)ide analogues. J Vir Hep. 2013. 20 (5): 322-327.
  1. Claassen MAA, de Knegt RJ, Turgut D, Groothuismink ZMA, Janssen HLA, Boonstra A. Negative regulation of hepatitis C virus specific immunity is highly heterogeneous and modulated by pegylated interferon-alpha/ribavirin therapy. PLoS ONE. 7(11): e49389.
  1. Van de Laar LA, van den Bosch A, Boonstra A, Binda RS, Buitenhuis M, Janssen HLA, Coffer PJ, Woltman AM. PI3K-PKB hyperactivation augments human plasmacytoid dendritic cell development and function. 2012. 120 (25): 4982-4891.
  1. Spaan M, Janssen HLA, Boonstra A. Immunology of hepatitis C infections. Review. Best Pract Res Clin Gastroenterol. 26(4): 391-400.
  1. Verstrepen B, de Groot N, Groothuismink ZMA, Verschoor E, Bogers W, Janssen HLA, Mooij P, Bontrop R, Koopman G, Boonstra A. Evaluation of IL-28B polymorphisms and serum IP-10 in hepatitis C infected chimpanzees. PLoS ONE. 7(10): e46645.
  1. Movita D, Kreefft K, van Oudenaren A, Leenen PJ, Janssen HLA, Boonstra A. Kupffer cells express a unique combination of phenotypic and functional characteristics compared with splenic and peritoneal macrophages. J Leukocyte Biol. 92 (4): 723-733.
  1. Liu BS, Janssen HLA, Boonstra A. Type I and III interferon enhance IL-10-induced STAT3 phosphorylation in human monocytes and macrophages, at least partly via augmented IL-10 receptor expression. Eur J Immunol. 42 (9): 2431-2440.

 

  1. Tjwa ETTL, van Oord GW, Biesta P, Boonstra A, Janssen HLA, Woltman AM. Restoration of TLR3-activated myeloid dendritic cell activity leads to improved natural killer cell function in chronic hepatitis B. J Virology. 2012. 86(8): 4102-4109.
  1. Roomer R, Bergmann JF, Boonstra A, Hansen BE, Haagmans B, Kwadijk-de Gijsel S, van Vuuren AJ, de Knegt RJ, Janssen HLA. Continuous interferon alfa-2b infusion in combination with ribavirin for chronic hepatitis C in treatment experienced patients. Antiviral Therapy. 2012. 17: 509-517.

 

  1. Boonstra A, B-S. Liu, Z.M.A. Groothuismink, J.F. Bergmann, J. de Bruijne, DM Hotho, B. Hansen, AA van Vliet, J. van de Wetering, S.P. Fletcher, L.A. Bauman, M. Rahimy, J.R. Appleman, JL Freddo, HW Reesink, RJ de Knegt, HLA. Janssen. Potent immune activation in chronic hepatitis C patients upon administration of an oral inducer of endogenous interferons that acts via TLR7. Antiviral Therapy. 17(4): 657-667.
  1. Shi CC, Tjwa ETTL, Biesta PJ, Boonstra A, Xie Q, Janssen HLA, Woltman AM. Hepatitis B virus suppresses the functional interaction between natural killer cells and plasmacytoid dendritic cells. J Vir Hep. 19:e26-33.
  1. Bergmann JF, de Bruijne J, Hotho DM, de Knegt RJ, Boonstra A, Weegink CJ, van Vliet AA, van de Wetering J, Fletcher SP, Bauman LA, Rahimy M, Appleman JR, Freddo JL, Janssen HL, Reesink HW. Randomized clinical trial: anti-viral activity of ANA773, an oral inducer of endogenous interferons acting via TLR7, in chronic HCV. Alim Pharm Ther. 34(4): 443-453.
  1. Peng C, Liu B-S, de Knegt RJ, Janssen HLA, Boonstra A. The response to TLR ligation of human CD16+CD14– monocytes is weakly modulated as a consequence of persistent infection with the hepatitis C virus. Mol Immunol. 48: 1505-1511.
  1. Claassen MAA, de Knegt, RJ, Janssen HLA, Boonstra A. Retention of CD4+CD25+FoxP3+ regulatory T cells in the liver after therapy-induced hepatitis C virus eradication in humans. J Virology. 85(11): 5323-5330.
  1. Liu B-S, Groothuismink ZMA, Janssen HLA, Boonstra A. Role for IL-10 in inducing functional impairment of monocytes upon TLR4 ligation in patients with chronic HCV infections. J Leukocyte Biol. 89(6): 981-988.
  1. Liu B-S, Janssen HLA, Boonstra A. IL-29 and IFNα differ in their ability to modulate IL-12 production by TLR-activated human macrophages, and exhibit differential regulation of the IFNg receptor expression. 2011. 117(8): 2385-2395.
  1. Redford PS, Boonstra A, Read S, Pitt, J, Graham C, Stavropoulos E, Bancroft GJ, O’Garra A. Enhanced protection to Mycobacterium tuberculosis infection in IL-10-deficient mice is accompanied by early and enhanced Th1 responses in the lung. Eur J Immunol. 40: 2200-2210.
  1. Grotenhuis BA, Franken PF, Swinkels WJC, Boonstra A, van der Valk MA, van Lanschot JJB, Fodde R. Early morbidity encountered in the dietary-related mouse model of Barrett’s esophagus: a question of zinc? Dis Esophagus. 24: 371-373.
  1. Arends JE, Claassen MAA, van den Berg CHSB, Nanlohy NM, van Erpecum KJ, Baak BC, Hoepelman AIM, Boonstra A, van Baarle D. T-cell responses at baseline and during therapy with peginterferon-a and ribavirin are not associated with outcome in chronic Hepatitis C infected patients. Antiviral Res. 87: 353-360.
  1. Claassen MAA, de Knegt RJ, Turgut D, Tilanus HW, Janssen HLA, Boonstra A. Abundant numbers of regulatory T cells localize to the liver of chronic hepatitis C infected patients and limit the extent of fibrosis. J Hepatol. 52: 315-321.
  1. Woltman AM, Boonstra A, Janssen HLA. Dendritic cells in chronic viral hepatitis: victims or guardian angels? 2010. 59: 115-125.
  1. Boonstra A, van der Laan LJW, Vanwolleghem T, Janssen HLA. Experimental models for hepatitis C viral infection. 2009. 50: 1646-1655.
  1. Woltman AM, ter Borg MJ, Binda RS, Sprengers D, von Blomberg BME, Scheper RJ, Hayashi K, Nishi N, Boonstra A, van der Molen R, Janssen a-Galactosylceramide in chronic hepatitis B infection: results from a randomized placebo controlled phase I/II trial. Antivir Ther. 2009. 14: 809-818.
  1. Liu B, Janssen HLA, Boonstra A. Modulation of dendritic cell function by persistent viruses. Review. J Leukoc Biol. 85: 205-214.
  1. Stoop JN, Claassen MAA, Woltman AM, Binda RS, Kuipers EJ, Janssen HLA, van der Molen RG, Boonstra A. Intrahepatic regulatory T cells are phenotypically distinct from their peripheral counterparts in chronic HBV patients, and their frequency depends on the viral load. Clin Immunol. 129: 419-427.
  1. Boonstra A, Woltman AM, Janssen HLA. Immunology of hepatitis B and hepatitis C virus infections. Review. Best Pract Res Clin Gastroenterol. 22: 1049-1061.

 

  1. Boonstra A, Rasjbaum R, Holman M, Marques R, Asselin-Paturel C, Pereira J, Bates EEM, Akira S, Vieira P, Liu Y-J, Trinchieri G, O’Garra A. Macrophages and myeloid DC, but not plasmacytoid DC, produce IL-10 in response to MyD88- and TRIF-dependent TLR signals, and TLR-independent signals. J Immunol. 2006. 177: 7551-7558.
  1. Sponaas AM, Cadman ET, Voisine C, Harrison V, Boonstra A, O’Garra A, Langhorne J. Malaria infection changes the ability of splenic DC populations to stimulate antigen-specific T cells. J Exp Med. 2006. 203: 1427-1433.
  1. Asselin-Paturel C, Brizard G, Chemin K, Boonstra A, O’Garra A, Vicari A, Trinchieri G. Type I interferon dependence of plasmacytoid dendritic cell activation and migration. J Exp Med. 201: 1157-1167.
  1. Vieira PL, Christensen JR, Minaee S, O’Neill EJ, Barrat FJ, Boonstra A, Barthlott T, Stockinger B, Wraith DC, O’Garra A. IL-10 secreting regulatory T cells do not express FoxP3 but have comparable regulatory function to naturally occurring CD4+CD25+ regulatory T cells. J Immunol. 172: 5986-5993.

 

  1. Boonstra A, Asselin-Paturel C, Gilliet M, Crain C, Trinchieri G, Liu Y-J, O’Garra Flexibility of mouse classical and plasmacytoid-derived dendritic cells in directing T helper type 1 and 2 cell development: dependency on antigen dose and differential Toll-like receptor ligation. J Exp Med. 2003. 197: 101-109.
  1. Gilliet M, Boonstra A, Paturel C, Antonenko S, Xu X, Trinchieri G, O’Garra A, Liu Y-J. The development of murine plasmacytoid dendritic cell precursors is differentially regulated by Flt3-ligand and granulocyte/macrophage colony-stimulating factor. J Exp Med. 195: 953-958 (cited 269 times).
  1. Barrat FJ, Boonstra A, Cua DJ, Richards DF, Crain C, Savelkoul HF, de Waal-Malefyt R, Coffman RL, Hawrylowicz CM, O’Garra A. In vitro generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med. 195: 603-616.
  1. Asselin-Paturel C, Boonstra A, Dalod M, Durand I, Yessaad N, Dezutter-Dambuyant C, Vicari A, O’Garra A, Biron C, Brière F, Trinchieri The major type I interferon producing cells in the mouse are immature antigen-presenting cells exhibiting plasmacytoid morphology. Nature Immunol. 2001. 2: 1144-1150.
  1. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HFJ, O’Garra A. 1,25-dihydroxy-vitamin D3 has a direct effect on naïve CD4+ T cells to enhance the development of Th2 cells. J Immunol. 167: 4974-4980.
  1. Boonstra A, van Oudenaren A, Baert M, van Steeg H, Leenen PJ, van Der Horst GT, Hoeijmakers JH, Savelkoul HF, Garssen J. Ultraviolet-B-induced immunomodulation in XPA, XPC, and CSB DNA repair-deficient mice. J Invest Dermatol. 117: 141-146.
  1. Boonstra A, van Oudenaren A, Barendregt B, An L, Leenen PJM, Savelkoul HFJ. Ultraviolet B irradiation modulates systemic immune responses by affecting cytokine production of antigen-presenting cells. Int Immunol. 12: 1531-1538.
  1. Van Loveren H, Boonstra A, van Dijk MEA, Fluitman AJM, Savelkoul HFJ, Garssen J. UV exposure alters respiratory allergic responses in mice. Photochem Photobiol. 72: 253-259.
  1. Grinwis GCM, Boonstra A, van den Brandhof EJ, Dormans JAMA, Engelsma M, Kuiper RV, van Loveren H, Wester PW, Vaal MA, Vos JG. Short-term toxicity of bis(tri-n-butyltin)oxide in flounder (Platichtys flesus): Pathology and immune function. Aquatic Toxicology. 1998, 42: 15-36.
  1. Boonstra A, Savelkoul HFJ. The role of cytokines in ultraviolet-B induced immunosuppression. Eur Cytokine Network. 8: 117-123.